Dr Tom Jenkins
MBChB MRCP PhD
Department of Neuroscience
Senior Clinical Lecturer
Co-Director MND Care Centre
Course Lead, MSc Clinical Neurology
+44 114 215 9101
Full contact details
Department of Neuroscience
385a Glossop Road
Dr Jenkins studied Medicine at the University of Manchester and obtained his PhD in Clinical Neuroscience from the UCL Institute of Neurology, Queen Square in 2010. His specialist clinical interest is neuromuscular disease and area of research expertise is neuroimaging.
He has experience in running longitudinal clinical, imaging and neurophysiological studies with the aim of developing tools to decipher disease mechanisms and facilitate future clinical trials in motor neuron disease (MND) and other neurodegenerative disorders.
Current areas of novel investigation include whole-body muscle imaging of denervation in MND and 31-phosphorus spectroscopy to assess energy metabolism in several neurodegenerative conditions.
Dr Jenkins is Principal Investigator on current and forthcoming studies and clinical trials in MND.
- Research interests
Magnetic resonance imaging (MRI) has revolutionised the practice of clinical neurology, and represents a powerful and safe tool with which to investigate people in research studies. There is no radiation involved in the scans and MRI offers a window with which to study disease mechanisms in living patients.
This is crucial in neurodegenerative diseases, which remain incompletely understood. MRI also has potential as a biomarker, with which to investigate the effect of new treatments, so important in these currently incurable conditions, to reduce the duration and expense of clinical trials, enabling more new treatments to be tested.
I am a clinical researcher and my approach is to combine clinical assessment and neurophysiology with advanced imaging techniques in vivo to provide multi-faceted insights into neurological disease.
Examples include application of 31-phosphorus spectroscopy to investigate energy dynamics, and whole-body muscle MRI to assess denervation, in patients with motor neuron disease (MND) and other neurodegenerative disorders.
Supported by charitable grant funding from the MRC, MNDA, British Medical Association (Vera Down grant), Ryder-Briggs, Neurocare, the NIHR Sheffield Biomedical Research Centre, current projects include the application of 31-phosphorus spectroscopy to study energy dynamics in patients with motor neuron disease, Parkinson’s disease and multiple sclerosis, glutathione spectroscopy and wet biomarkers to investigate oxidative stress in MND, and clinical and genetic profiling in a variety of motor neuron disorders.
I am also Principal Investigator for several current and forthcoming studies in MND, sponsored by Biogen.
- Value of systematic genetic screening of patients with amyotrophic lateral sclerosis.. J Neurol Neurosurg Psychiatry.
- EAN consensus statement for management of patients with neurological diseases during the COVID‐19 pandemic. European Journal of Neurology, 28(1), 7-14. View this article in WRRO
- Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. BMJ Open, 10(8), e038911-e038911.
- Correction to: Longitudinal multi-modal muscle-based biomarker assessment in motor neuron disease. Journal of Neurology, 267(1), 257-258.
- Limb girdle muscular dystrophy: a case report initially presenting to an outpatient musculoskeletal physiotherapy clinic with spinal pain and functional weakness. Archives of Physiotherapy, 9(1).
- Cognitive deficits in vasculitis of the nervous system: a cross-sectional study. Postgraduate Medicine, 131(7), 546-549.
- Biomarkers in Motor Neuron Disease: A State of the Art Review. Frontiers in Neurology, 10. View this article in WRRO
- Structural cortical network reorganization associated with early conversion to multiple sclerosis. Scientific Reports, 8(1).
- Response to Finsterer: CPT-II deficiency needs to be detected in army personnel. Molecular Genetics and Metabolism Reports, 16, 12-12. View this article in WRRO
- Recurrent rhabdomyolysis caused by carnitine palmitoyltransferase II deficiency, common but under-recognised: Lessons to be learnt. Molecular Genetics and Metabolism Reports, 15, 69-70. View this article in WRRO
- Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. Journal of the Neurological Sciences, 388, 79-83.
- Translational approaches to restoring mitochondrial function in Parkinson's disease. FEBS Letters, 592(5), 776-792. View this article in WRRO
- Imaging muscle as a potential biomarker of denervation in motor neuron disease. Journal of Neurology, Neurosurgery, and Psychiatry, 89, 248-255. View this article in WRRO
- 1736 Diagnostic classification of lower motor neuron disorders. Journal of Neurology, Neurosurgery & Psychiatry, 88(Suppl 1), A5.2-A5.
- Optic neuritis. Current Opinion in Neurology, 30(1), 61-66. View this article in WRRO
- The role of cranial and thoracic electromyography within diagnostic criteria for amyotrophic lateral sclerosis. Muscle & Nerve, 54(3), 378-385. View this article in WRRO
- A wolf in sheep's clothing. Practical Neurology, 16(2), 153-156.
- Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis. Brain, 139(3), 816-828.
- Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: No. Multiple Sclerosis Journal, 20(10), 1299-1301.
- The evidence for symptomatic treatments in amyotrophic lateral sclerosis. Current Opinion in Neurology, 27(5), 524-531.
- Clinical and Molecular Aspects of Motor Neuron Disease. Colloquium Series on Genomic and Molecular Medicine, 2(2), 1-60.
- A prospective pilot study measuring muscle volumetric change in amyotrophic lateral sclerosis.. Amyotroph Lateral Scler Frontotemporal Degener, 14(5-6), 414-423. View this article in WRRO
- The cost of long hospital stays. Clinical Medicine, Journal of the Royal College of Physicians of London, 12(1), 98-99.
- Multiple sclerosis in an adrenoleukodystrophy carrier.. Clin Pract, 1(4), e125.
- Early pericalcarine atrophy in acute optic neuritis is associated with conversion to multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 82(9), 1017-1021.
- A longitudinal functional MRI study of non-arteritic anterior ischaemic optic neuropathy patients.. J Neurol Neurosurg Psychiatry, 82(8), 905-913.
- . BMJ, 343(oct19 3), d6651-d6651.
- Reply. Annals of Neurology, 68(6), 971.
- Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis.. Mult Scler, 16(5), 555-565.
- Comments on "Neuroplasticity predicts outcome of optic neuritis independent of tissue damage": Reply. Annals of Neurology, 67(4), 551-552.
- Disease modifying therapies in multiple sclerosis.. Int J Clin Pract, 64(5), 532-534.
- Dissecting structure-function interactions in acute optic neuritis to investigate neuroplasticity. Human Brain Mapping, 31(2), 276-286.
- Neuroplasticity predicts outcome of optic neuritis independent of tissue damage.. Ann Neurol, 67(1), 99-113.
- Diagnosing and managing multiple sclerosis.. The Practitioner, 253(1721).
- Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis.. J Neurol, 256(3), 305-319.
- Contiguous-slice zonally oblique multislice (CO-ZOOM) diffusion tensor imaging: examples of in vivo spinal cord and optic nerve applications.. J Magn Reson Imaging, 29(2), 454-460.
- Oculopharyngeal myopathy with inflammation and calcinosis: an unusual phenotype.. J Neurol Neurosurg Psychiatry, 79(6), 731-733.
- Diagnosis and management of primary progressive multiple sclerosis.. Minerva Med, 99(2), 141-155.
- GPs have pivotal role in managing MS.. Practitioner, 251(1694), 37-passim.
- Spinal neuropathic osteoarthropathy (Charcot) disease resulting in a traumatic subarachnoid haemorrhage. European Journal of Radiology Extra, 58(3), 73-76.
- Spastic Paresis in Paget's Disease. Journal of the Royal Society of Medicine, 98(8), 366-368.
- A dysphasic diabetic with confusion and fever. Practical Neurology, 5(4), 230-235.
- Spastic paresis in Paget's disease.. J R Soc Med, 98(8), 366-368.
- A plea for equitable global access to COVID‐19 diagnostics, vaccination and therapy: the NeuroCOVID‐19 task Force of the european Academy of neurology. European Journal of Neurology.
- Primary prevention of COVID‐19: advocacy for vaccination from a neurological perspective. European Journal of Neurology.
- Simultaneous ALS and SCA2 associated with an intermediate-length ATXN2 CAG-repeat expansion. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 1-3.
- Diagnostic and investigative approach of consultant neurologists in a real‐world clinical setting: a pilot study. International Journal of Clinical Practice.
- Neurological letter from Bangladesh. Practical Neurology.
- The international European Academy of Neurology survey on neurological symptoms in patients with COVID‐19 infection. European Journal of Neurology.
- New developments in the treatment of optic neuritis. Eye and Brain, 83-83.
- Longitudinal multi-modal muscle-based biomarker assessment in motor neuron disease. Journal of Neurology. View this article in WRRO
- View this article in WRRO Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis. Brain.
- Visual Acuity, Eye Movements and Visual Fields, Pituitary Apoplexy (pp. 75-88). Springer Berlin Heidelberg
Conference proceedings papers
- 222 Investigating directionality of neurodegeneration in vivo in ALS using multimodal MRI. Journal of Neurology Neurosurgery & Psychiatry, Vol. 90(12) (pp e55)
- Defining benign brachial monomelic amyotrophy: factors at presentation that differentiate from motor neurone disease. EUROPEAN JOURNAL OF NEUROLOGY, Vol. 26 (pp 307-307)
- Investigating Directionality of Neurodegeneration in vivo in ALS using Multimodal MRI. NEUROLOGY, Vol. 92(15)
- Predicting benign brachial monomelic amyotrophy: factors at presentation that differentiate from amyotropic lateral sclerosis. NEUROLOGY, Vol. 92(15)
- Imaging denervation in amyotrophic lateral sclerosis for future clinical trials: 12-month follow-up from a longitudinal cohort study. EUROPEAN JOURNAL OF NEUROLOGY, Vol. 25 (pp 302-302)
- PO215 Outcomes of neurology admissions to critical care. Journal of Neurology, Neurosurgery & Psychiatry, Vol. 88(Suppl 1) (pp A68.3-A68)
- Imaging denervation in motor neuron disease for future clinical trials: a longitudinal cohort study. Journal of the Neurological Sciences, Vol. 381 (pp 102-102) View this article in WRRO
- THE COST OF LONG NEUROLOGY INPATIENT STAYS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol. 83(3)
- Teaching activities
In addition to the Clinical Neurology MSc, I give lectures, seminars and clinical demonstrations on a 1-2 weekly basis to pre-clinical and clinical medical and dental students, nurses, junior doctors, medical registrars, psychiatrists, physiotherapists, engineers, hospice staff, and university alumni.
The lectures cover a wide range of aspects of clinical neurology, from the features of neuromuscular diseases in which I specialise, through to more diverse neurological topics, such as the neuroanatomical basis of emotions.
- Professional activities
I am Co-Director of the Sheffield MNDA Care Centre. I lead the MSc in Clinical Neurology at the University of Sheffield. I was recently appointed Editor of the European Association of Neurologists EAN Pages website, which serves 45,000 neurologists.
I am Principal Investigator (PI) for the Neuroimaging Society on Amyotrophic Lateral Sclerosis (NiSALS) collaboration, for the current Biogen-sponsored Methodology study and for a forthcoming Biogen gene silencing trial in MND. I lead an imaging research group of PhD and MSc students.